Exome Asset Management LLC Invests $2.17 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Exome Asset Management LLC bought a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 176,600 shares of the company’s stock, valued at approximately $2,170,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Stoke Therapeutics by 16.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter. Quest Partners LLC bought a new position in shares of Stoke Therapeutics during the 2nd quarter valued at approximately $29,000. Los Angeles Capital Management LLC grew its holdings in shares of Stoke Therapeutics by 7.2% in the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after purchasing an additional 4,508 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Stoke Therapeutics by 14.3% in the second quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock worth $647,000 after purchasing an additional 5,990 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners assumed coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $20.83.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company’s stock, valued at $618,913.39. This represents a 16.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,000,349 shares of company stock valued at $28,031,296. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Stock Down 2.1 %

Shares of NASDAQ:STOK opened at $12.06 on Friday. The stock has a market cap of $638.82 million, a P/E ratio of -5.74 and a beta of 0.95. Stoke Therapeutics, Inc. has a 52-week low of $4.09 and a 52-week high of $17.58. The business’s 50 day moving average is $12.49 and its 200 day moving average is $13.65.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.